# 616437

FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 616437 AD 3 SQSTM1 601530
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
HEAD & NECK
Face
- Orofacial apraxia
RESPIRATORY
- Bulbar weakness
ABDOMEN
Gastrointestinal
- Swallowing difficulties
- Dysphagia
SKELETAL
- Paget disease of bone (in some patients)
MUSCLE, SOFT TISSUES
- Muscle weakness
- Amyotrophy
- Fasciculations
- Fibrillations
NEUROLOGIC
Central Nervous System
- Frontotemporal dementia
- Amyotrophic lateral sclerosis
- Language impairment
- Decreased fluency
- Upper motor neuron signs
- Lower motor neuron signs
- Dysarthria
- Mutism
- Hyperreflexia
- Hyporeflexia
- Cortical atrophy
Behavioral Psychiatric Manifestations
- Executive dysfunction
- Disinhibition
- Personality changes
- Abnormal behavior
- Apathy
MISCELLANEOUS
- Onset in late adulthood
- Progressive disorder
- Patients may have either dementia or motor neuron disease or both
- Phenotypic variability
MOLECULAR BASIS
- Caused by mutation in the sequestosome 1 gene (SQSTM1, 601530.0001)
Frontotemporal dementia and/or Amyotrophic Lateral Sclerosis - PS105550 - 4 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
Amyotrophic lateral sclerosis - PS105400 - 35 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.22 Frontotemporal lobar degeneration, TARDBP-related AD 3 612069 TARDBP 605078
1p36.22 Amyotrophic lateral sclerosis 10, with or without FTD AD 3 612069 TARDBP 605078
2p13.1 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 DCTN1 601143
2q33.1 Amyotrophic lateral sclerosis 2, juvenile AR 3 205100 ALS2 606352
2q34 Amyotrophic lateral sclerosis 19 AD 3 615515 ERBB4 600543
2q35 Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia AD 3 616208 TUBA4A 191110
3p11.2 Amyotrophic lateral sclerosis 17 AD 3 614696 CHMP2B 609512
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} AD 3 617892 NEK1 604588
5q31.2 Amyotrophic lateral sclerosis 21 AD 3 606070 MATR3 164015
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
6q21 Amyotrophic lateral sclerosis 11 AD 3 612577 FIG4 609390
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
9p13.3 ?Amyotrophic lateral sclerosis 16, juvenile AR 3 614373 SIGMAR1 601978
9p13.3 Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia 3 613954 VCP 601023
9q34.13 Amyotrophic lateral sclerosis 4, juvenile AD 3 602433 SETX 608465
10p13 Amyotrophic lateral sclerosis 12 3 613435 OPTN 602432
10q22.3 Amytrophic lateral sclerosis 23 AD 3 617839 ANXA11 602572
12q13.12 {Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 PRPH 170710
12q13.13 Amyotrophic lateral sclerosis 20 AD 3 615426 HNRNPA1 164017
12q13.3 {Amyotrophic lateral sclerosis, susceptibility to, 25} AD 3 617921 KIF5A 602821
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
12q24.12 {Amyotrophic lateral sclerosis, susceptibility to, 13} AD 3 183090 ATXN2 601517
12q24.12 Spinocerebellar ataxia 2 AD 3 183090 ATXN2 601517
14q11.2 Amyotrophic lateral sclerosis 9 3 611895 ANG 105850
15q21.1 Amyotrophic lateral sclerosis 5, juvenile AR 3 602099 SPG11 610844
16p11.2 Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 3 608030 FUS 137070
17p13.2 Amyotrophic lateral sclerosis 18 3 614808 PFN1 176610
18q21 Amyotrophic lateral sclerosis 3 AD 2 606640 ALS3 606640
20p13 Amyotrophic lateral sclerosis 7 2 608031 ALS7 608031
20q13.32 Amyotrophic lateral sclerosis 8 AD 3 608627 VAPB 605704
21q22.11 Amyotrophic lateral sclerosis 1 AR, AD 3 105400 SOD1 147450
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
22q12.2 ?{Amyotrophic lateral sclerosis, susceptibility to} AR, AD 3 105400 NEFH 162230
Xp11.21 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia XLD 3 300857 UBQLN2 300264
Not Mapped Amyotrophic lateral sclerosis, juvenile, with dementia 205200 ALSDC 205200

TEXT

A number sign (#) is used with this entry because of evidence that frontotemporal dementia and/or amyotrophic lateral sclerosis-3 (FTDALS3) is caused by heterozygous mutation in the SQSTM1 gene (601530) on chromosome 5q35.

Heterozygous mutation in the SQSTM1 gene can also cause Paget disease of bone (PDB3; 167250).


Description

Frontotemporal dementia and/or amyotrophic lateral sclerosis-3 is an autosomal dominant neurodegenerative disorder characterized by adult or late adult onset of cognitive impairment, behavioral abnormalities, and speech apraxia and/or upper and lower motor neuron signs. Some patients may also develop Paget disease of bone. The phenotype is highly variable, even within families (summary by Rea et al., 2014).

For a discussion of genetic heterogeneity of FTDALS, see FTDALS1 (105550).


Clinical Features

Hirano et al. (2013) reported 2 unrelated Japanese patients with onset of ALS at ages 59 and 76 years, respectively. Symptoms were variable but included progressive muscle weakness and atrophy, hyporeflexia, dysarthria, bulbar weakness, fasciculations, and hyperreflexia. Electromyography showed fibrillations, suggesting active denervation. Neither patient had apparent dementia, but both eventually became bedridden and needed assisted feeding and ventilation.

Le Ber et al. (2013) reported 4 French families with FTDALS3. Patients in 3 families presented with behavioral disorders consistent with FTD, including executive dysfunction, indifference, disinhibition, echolalia, apathy, and irritability. Only 1 patient developed distal motor deficits, amyotrophy, buccofacial apraxia, hyperreflexia, and fasciculations, consistent with ALS. Three patients from the fourth family presented with Paget disease of bone and later developed dementia; 1 patient from this family presented with dementia and also had PDB. None of these patients had ALS. The report demonstrated the inter- and intrafamilial variability of neurodegenerative features associated with SQSTM1 mutations.

Boutoleau-Bretonniere et al. (2015) reported 3 French sibs with a variant of FTD. The phenotype consisted of speech apraxia, visuoconstructional defects, executive dysfunction, and behavioral disorders with onset between 70 and 75 years of age. None of the patients had evidence of PDB or ALS.


Molecular Genetics

Fecto et al. (2011) identified 9 different heterozygous missense mutations (see, e.g., P392L, 601530.0001 and A33V, 601530.0006) and 1 deletion in the SQSTM1 gene in 15 (2.8%) of 546 patients with amyotrophic lateral sclerosis. Six patients had a family history of the disorder, but DNA from relatives was not available for segregation analysis. All the mutations affected conserved residues, and none were present in the dbSNP or 1000 Genomes Project databases or in over 700 control individuals. Functional studies of the variants were not performed. The SQSTM1 gene was chosen as a candidate for direct sequencing because p62-positive aggregates have been found in neuronal and glial tissue from patients with various neurodegenerative disorders, including SOD1 (147450)-positive ALS1 (105400), Alzheimer disease (AD; 104300), Lewy body dementia (DLB; 127750), FUS (137070)-mutant ALS6 (608030), and FTDALS1 (105550). None of the patients had a personal or family history of PDB.

By direct sequencing of the SQSTM1 gene, Rubino et al. (2012) identified 3 missense variants in 3 of 170 Italian patients with FTD and 3 different missense variants in 3 of 124 Italian patients with ALS. None of the variants were found in 145 controls. Subsequent analysis identified 4 variants in the promoter region in 4 patients with FTD and 3 splice site variants in 1 patient with FTD and 3 with ALS. None of the variants were found in 145 control individuals or in 288 patients with Paget disease. Functional studies were not performed, and Rubino et al. (2012) suggested that further studies were warranted.

Hirano et al. (2013) identified 2 different heterozygous missense variants (A53T and P439L) in the SQSTM1 gene in 2 of 61 Japanese patients with ALS. Neither of the variants, which occurred at highly conserved residues, were detected in the dbSNP database or in 500 control Japanese chromosomes. Both patients had sporadic disease, yielding a frequency of 3.7% among 54 patients with sporadic ALS. Neither patient had evidence of Paget disease or dementia; functional studies of the variants were not performed.

Le Ber et al. (2013) identified 3 different heterozygous missense mutations in the SQSTM1 gene (see, e.g., 601530.0001 and 601530.0005) in 3 of 132 unrelated French families with FTD. The mutations were demonstrated to segregate with the disorder in 2 of the families. A heterozygous missense mutation (601530.0006) was found in 1 of 56 probands with FTDALS. The mutation in the first family was found by exome sequencing; subsequent mutations were found by directed sequencing of the SQSTM1 gene in 187 French patients with FTD. In the family carrying the P392L mutation (601530.0001), all patients with FTD also had PDB. Functional studies of the variants were not performed. Overall, mutations were found in 4 (2%) of 188 patients with either FTD or FTDALS, indicating a low frequency of SQSTM1 mutations in FTD.

In 3 French sibs with a variant of frontotemporal dementia, Boutoleau-Bretonniere et al. (2015) identified a heterozygous mutation in the SQSTM1 gene (601530.0007).


Pathogenesis

Rea et al. (2014) reviewed potential pathogenic mechanisms resulting from mutations in the SQSTM1 gene, noting in particular the role of abnormal NFKB1 (164011) signaling and defective ubiquitin-mediated autophagy in neurodegeneration. However, Rea et al. (2014) noted that functional studies of variants found in patients with FTDALS3 had not been performed in cell lines used in ALS or FTD research or in neuronal cells. Some of the mechanisms were reminiscent of those caused by mutation in OPTN (602432), which causes ALS12 (613435); VCP (601023), which causes IBMPFD1 (167320); and UBQLN2 (300264), which causes ALS15 (300857).


REFERENCES

  1. Boutoleau-Bretonniere, C., Camuzat, A., Le Ber, I., Bouya-Ahmed, K., Guerreiro, R., Deruet, A.-L., Evrard, C., Bras, J., Lamy, E., Auffray-Calvier, E., Pallardy, A., Hardy, J., Brice, A., Derkinderen, P., Vercelletto, M. A phenotype of atypical apraxia of speech in a family carrying SQSTM1 mutation. J. Alzheimers Dis. 43: 625-630, 2015. [PubMed: 25114083, images, related citations] [Full Text]

  2. Fecto, F., Yan, J., Vemula, S. P., Liu, E., Yang, Y., Chen, W., Zheng, J. G., Shi, Y., Siddique, N., Arrat, H., Donkervoort, S., Ajroud-Driss, S., Sufit, R. L., Heller, S. L., Deng, H.-X., Siddique, T. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 68: 1440-1446, 2011. [PubMed: 22084127, related citations] [Full Text]

  3. Hirano, M., Nakamura, Y., Saigoh, K., Sakamoto, H., Ueno, S., Isono, C., Miyamoto, K., Akamatsu, M., Mitsui, Y., Kusunoki, S. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology 80: 458-463, 2013. [PubMed: 23303844, related citations] [Full Text]

  4. Le Ber, I., Camuzat, A., Guerreiro, R., Bouya-Ahmed, K., Bras, J., Nicolas, G., Gabelle, A., Didic, M., De Septenville, A., Millecamps, S., Lenglet, T., Latouche, M., Kabashi, E., Campion, D., Hannequin, D., Hardy, J., Brice, A. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 70: 1403-1410, 2013. [PubMed: 24042580, images, related citations] [Full Text]

  5. Rea, S. L., Majcher, V., Searle, M. S., Layfield, R. SQSTM1 mutations--bridging Paget disease of bone and ALS/FTD. Exp. Cell Res. 325: 27-37, 2014. [PubMed: 24486447, related citations] [Full Text]

  6. Rubino, E., Rainero, I., Chio, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., Bruni, A. C., St. George-Hyslop, P. H., Scarpini, E., Gallone, S., Pinessi, L. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79: 1556-1562, 2012. [PubMed: 22972638, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 6/24/2015
alopez : 11/08/2016
carol : 06/30/2015
mcolton : 6/30/2015
mcolton : 6/30/2015
mcolton : 6/30/2015
ckniffin : 6/29/2015

# 616437

FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 3; FTDALS3


ORPHA: 803, 275872, 275864;   DO: 0110068;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 616437 Autosomal dominant 3 SQSTM1 601530

TEXT

A number sign (#) is used with this entry because of evidence that frontotemporal dementia and/or amyotrophic lateral sclerosis-3 (FTDALS3) is caused by heterozygous mutation in the SQSTM1 gene (601530) on chromosome 5q35.

Heterozygous mutation in the SQSTM1 gene can also cause Paget disease of bone (PDB3; 167250).


Description

Frontotemporal dementia and/or amyotrophic lateral sclerosis-3 is an autosomal dominant neurodegenerative disorder characterized by adult or late adult onset of cognitive impairment, behavioral abnormalities, and speech apraxia and/or upper and lower motor neuron signs. Some patients may also develop Paget disease of bone. The phenotype is highly variable, even within families (summary by Rea et al., 2014).

For a discussion of genetic heterogeneity of FTDALS, see FTDALS1 (105550).


Clinical Features

Hirano et al. (2013) reported 2 unrelated Japanese patients with onset of ALS at ages 59 and 76 years, respectively. Symptoms were variable but included progressive muscle weakness and atrophy, hyporeflexia, dysarthria, bulbar weakness, fasciculations, and hyperreflexia. Electromyography showed fibrillations, suggesting active denervation. Neither patient had apparent dementia, but both eventually became bedridden and needed assisted feeding and ventilation.

Le Ber et al. (2013) reported 4 French families with FTDALS3. Patients in 3 families presented with behavioral disorders consistent with FTD, including executive dysfunction, indifference, disinhibition, echolalia, apathy, and irritability. Only 1 patient developed distal motor deficits, amyotrophy, buccofacial apraxia, hyperreflexia, and fasciculations, consistent with ALS. Three patients from the fourth family presented with Paget disease of bone and later developed dementia; 1 patient from this family presented with dementia and also had PDB. None of these patients had ALS. The report demonstrated the inter- and intrafamilial variability of neurodegenerative features associated with SQSTM1 mutations.

Boutoleau-Bretonniere et al. (2015) reported 3 French sibs with a variant of FTD. The phenotype consisted of speech apraxia, visuoconstructional defects, executive dysfunction, and behavioral disorders with onset between 70 and 75 years of age. None of the patients had evidence of PDB or ALS.


Molecular Genetics

Fecto et al. (2011) identified 9 different heterozygous missense mutations (see, e.g., P392L, 601530.0001 and A33V, 601530.0006) and 1 deletion in the SQSTM1 gene in 15 (2.8%) of 546 patients with amyotrophic lateral sclerosis. Six patients had a family history of the disorder, but DNA from relatives was not available for segregation analysis. All the mutations affected conserved residues, and none were present in the dbSNP or 1000 Genomes Project databases or in over 700 control individuals. Functional studies of the variants were not performed. The SQSTM1 gene was chosen as a candidate for direct sequencing because p62-positive aggregates have been found in neuronal and glial tissue from patients with various neurodegenerative disorders, including SOD1 (147450)-positive ALS1 (105400), Alzheimer disease (AD; 104300), Lewy body dementia (DLB; 127750), FUS (137070)-mutant ALS6 (608030), and FTDALS1 (105550). None of the patients had a personal or family history of PDB.

By direct sequencing of the SQSTM1 gene, Rubino et al. (2012) identified 3 missense variants in 3 of 170 Italian patients with FTD and 3 different missense variants in 3 of 124 Italian patients with ALS. None of the variants were found in 145 controls. Subsequent analysis identified 4 variants in the promoter region in 4 patients with FTD and 3 splice site variants in 1 patient with FTD and 3 with ALS. None of the variants were found in 145 control individuals or in 288 patients with Paget disease. Functional studies were not performed, and Rubino et al. (2012) suggested that further studies were warranted.

Hirano et al. (2013) identified 2 different heterozygous missense variants (A53T and P439L) in the SQSTM1 gene in 2 of 61 Japanese patients with ALS. Neither of the variants, which occurred at highly conserved residues, were detected in the dbSNP database or in 500 control Japanese chromosomes. Both patients had sporadic disease, yielding a frequency of 3.7% among 54 patients with sporadic ALS. Neither patient had evidence of Paget disease or dementia; functional studies of the variants were not performed.

Le Ber et al. (2013) identified 3 different heterozygous missense mutations in the SQSTM1 gene (see, e.g., 601530.0001 and 601530.0005) in 3 of 132 unrelated French families with FTD. The mutations were demonstrated to segregate with the disorder in 2 of the families. A heterozygous missense mutation (601530.0006) was found in 1 of 56 probands with FTDALS. The mutation in the first family was found by exome sequencing; subsequent mutations were found by directed sequencing of the SQSTM1 gene in 187 French patients with FTD. In the family carrying the P392L mutation (601530.0001), all patients with FTD also had PDB. Functional studies of the variants were not performed. Overall, mutations were found in 4 (2%) of 188 patients with either FTD or FTDALS, indicating a low frequency of SQSTM1 mutations in FTD.

In 3 French sibs with a variant of frontotemporal dementia, Boutoleau-Bretonniere et al. (2015) identified a heterozygous mutation in the SQSTM1 gene (601530.0007).


Pathogenesis

Rea et al. (2014) reviewed potential pathogenic mechanisms resulting from mutations in the SQSTM1 gene, noting in particular the role of abnormal NFKB1 (164011) signaling and defective ubiquitin-mediated autophagy in neurodegeneration. However, Rea et al. (2014) noted that functional studies of variants found in patients with FTDALS3 had not been performed in cell lines used in ALS or FTD research or in neuronal cells. Some of the mechanisms were reminiscent of those caused by mutation in OPTN (602432), which causes ALS12 (613435); VCP (601023), which causes IBMPFD1 (167320); and UBQLN2 (300264), which causes ALS15 (300857).


REFERENCES

  1. Boutoleau-Bretonniere, C., Camuzat, A., Le Ber, I., Bouya-Ahmed, K., Guerreiro, R., Deruet, A.-L., Evrard, C., Bras, J., Lamy, E., Auffray-Calvier, E., Pallardy, A., Hardy, J., Brice, A., Derkinderen, P., Vercelletto, M. A phenotype of atypical apraxia of speech in a family carrying SQSTM1 mutation. J. Alzheimers Dis. 43: 625-630, 2015. [PubMed: 25114083] [Full Text: https://content.iospress.com/openurl?genre=article&id=doi:10.3233/JAD-141512]

  2. Fecto, F., Yan, J., Vemula, S. P., Liu, E., Yang, Y., Chen, W., Zheng, J. G., Shi, Y., Siddique, N., Arrat, H., Donkervoort, S., Ajroud-Driss, S., Sufit, R. L., Heller, S. L., Deng, H.-X., Siddique, T. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 68: 1440-1446, 2011. [PubMed: 22084127] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneurol.2011.250]

  3. Hirano, M., Nakamura, Y., Saigoh, K., Sakamoto, H., Ueno, S., Isono, C., Miyamoto, K., Akamatsu, M., Mitsui, Y., Kusunoki, S. Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology 80: 458-463, 2013. [PubMed: 23303844] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=23303844]

  4. Le Ber, I., Camuzat, A., Guerreiro, R., Bouya-Ahmed, K., Bras, J., Nicolas, G., Gabelle, A., Didic, M., De Septenville, A., Millecamps, S., Lenglet, T., Latouche, M., Kabashi, E., Campion, D., Hannequin, D., Hardy, J., Brice, A. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 70: 1403-1410, 2013. [PubMed: 24042580] [Full Text: https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2013.3849]

  5. Rea, S. L., Majcher, V., Searle, M. S., Layfield, R. SQSTM1 mutations--bridging Paget disease of bone and ALS/FTD. Exp. Cell Res. 325: 27-37, 2014. [PubMed: 24486447] [Full Text: https://linkinghub.elsevier.com/retrieve/pii/S0014-4827(14)00040-8]

  6. Rubino, E., Rainero, I., Chio, A., Rogaeva, E., Galimberti, D., Fenoglio, P., Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., Bruni, A. C., St. George-Hyslop, P. H., Scarpini, E., Gallone, S., Pinessi, L. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79: 1556-1562, 2012. [PubMed: 22972638] [Full Text: http://www.neurology.org/cgi/pmidlookup?view=long&pmid=22972638]


Creation Date:
Cassandra L. Kniffin : 6/24/2015
Edit History:
alopez : 11/08/2016
carol : 06/30/2015
mcolton : 6/30/2015
mcolton : 6/30/2015
mcolton : 6/30/2015
ckniffin : 6/29/2015